Compare VMI & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VMI | KNSA |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United Kingdom |
| Employees | 10791 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 7.7B |
| IPO Year | 1994 | 2018 |
| Metric | VMI | KNSA |
|---|---|---|
| Price | $385.66 | $93.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | ★ $610.75 | $111.57 |
| AVG Volume (30 Days) | 162.5K | ★ 800.1K |
| Earning Date | 10-20-2026 | 10-27-2026 |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | N/A | ★ 225.00 |
| EPS | ★ 17.88 | 1.14 |
| Revenue | ★ $3,169,556,000.00 | $677,564,000.00 |
| Revenue This Year | $6.09 | $54.80 |
| Revenue Next Year | $7.43 | $28.50 |
| P/E Ratio | ★ $22.93 | $82.02 |
| Revenue Growth | 14.52 | ★ 60.09 |
| 52 Week Low | $379.28 | $37.02 |
| 52 Week High | $585.71 | $99.31 |
| Indicator | VMI | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 30.31 | 55.79 |
| Support Level | N/A | $87.30 |
| Resistance Level | $487.35 | $98.90 |
| Average True Range (ATR) | 13.46 | 3.99 |
| MACD | -0.86 | -0.60 |
| Stochastic Oscillator | 2.31 | 54.12 |
Valmont Industries Inc, along with its subsidiaries, operates as a manufacturer of products and services for infrastructure and agriculture markets. Its reportable segments are Infrastructure and Agriculture. The company generates maximum revenue from the Infrastructure segment, which includes the manufacturing and distribution of products and solutions to serve the infrastructure markets of utility, solar, lighting, transportation, and telecommunications, along with coatings services to protect metal products. The Agriculture segment provides irrigation equipment components, including aftermarket parts and tubular products, and technology solutions for precision agriculture. Geographically, it derives key revenue from the United States, followed by Australia, Brazil, and other regions.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.